Asset profile

aroxybutynin/atomoxetine · Apnimed, Inc. (APMD)

Indication
obstructive sleep apnea (OSA)
CompanyAPMDApnimed, Inc.

Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD10…

More from Apnimed, Inc.

Other drugs and candidates from the same company tracked in this sector.

aroxybutynin/atomoxetine · Apnimed, Inc. (APMD) — FDA Timeline & Readiness Checklist | SimianX AI